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TEMPORARY WITHDRAWAL OF IMMUNOSUPPRESSION FOR LIFE-THREATENING INFECTIONS AFTER 
LIVER TRANSPLANTATION) 
The outcome of a transplanted organ depends frequently 
upon the occurrence of allograft rejection and infection epi-
sodes. These 2 events are closely related. On one side, immu-
nosuppressive therapy is required to avoid allograft rejection, 
but on the other side this therapy facilitates the occurrence of 
infections (1). A better understanding of allograft rejection 
mechanisms along with new immunosuppressive therapies 
and antimicrobial prophylaxis has increased graft and pa-
tient survival. However, infectious complications continue to 
be a common cause of morbidity and mortality after organ 
transplantation: 
The managements of these infections depend primarily 
upon identification of infectious causative agents. Specific 
antibacterial, antiviral, antifungal, and antiprotozoal 
therapy provides the mainstay in treatment of these infec-
tions. However, it also is important to lower the immunosup-
pressive background to allow the host immunological re-
sponse to these infections, particularly when infections are 
considered life threatening. Although discontinuation of im-
munosuppression is a generally accepted option in these situ-
ations of life-threatening infections, no information it is 
available about graft and patient outcomes in these circum-
stances. In kidney transplantation, immunosuppression may 
be stopped completely in the setting oflife-threatening infec-
tions, since return to dialysis and retransplantation is always 
an option (2, 3). In contrast, in liver transplantation discon-
tinuation of immunosuppression is considered "very risky," 
because it may lead to graft loss and patient death. The 
following is a report of the circumstances and outcome of 
patients with life-threatening infectious complications after 
liver transplantation, all of whom were managed with a tem-
porary discontinuation of the immunosuppression therapy. 
Between 1987 and 1991, 31 patients underwent liver 
transplantation and developed severe opportunistic infec-
tions. The management included, along with the specific 
anti-infectious therapy, a temporary withdrawal of immuno-
suppression for at least 15 days. The patients were on 2 
different immunosuppressive protocols, as described previ-
ously (4): (1) CsA and steroids (12 patients) and (2) FK506 
with low dose steroids (19 patients). Table 1 shows the types 
of infection seen and the immunosuppression that patients 
were receiving. The change in their immunosuppression 
management followed 1 of 2 patterns when infection was 
diagnosed: total discontinuation of immunosuppressive 
agents (in 1 CsA and 19 FK506 patients) or a maintenance 
dose of5 mg/day prednisone only was given (11 CsApatients). 
1 This study was presented at the 11th Annual Meeting of the 
American Society of Transplant Physicians, May 26-27, 1992, 
Chicago, IL. 
Thirteen patients (42%; 5 CsA and 8 FK506 patients) died at 
a median time of 23 days after their immunosuppression 
therapy was discontinued (range 16-56 days) because of com-
plications related to the infections. Autopsy examination was 
performed in 8 of these patients, with no evidence of allograft 
rejection in any of them. 
Eighteen patients (7 CsA and 11 FK506) who survived had 
their immunosuppression discontinued at a median interval 
of 140 days (range 44-779) after liver transplantation. They 
were a median of 17 days (range 15--43) without detectable 
levels of CsA or FK506. All patients had their baseline im-
munosuppression resumed. However, the maintenance dose 
of either CsA and FK506 was reduced a median of 50% (range 
0-89%) in comparison with the baseline immunosuppression 
before the discontinuation. Only 4 patients (3 CsA, 1 FK506) 
required reinstitution of immunosuppression because of re-
jection. The median interval from liver transplantation to 
discontinuation of immunosuppression was 129 days (range 
44-411) in those patients who had rejection and 143 days 
(range 53-779) in patients who did not have rejection (NS). 
The median period with undetectable levels ofCsA or FK506 
was 27 days (range 2(43) in those patients who had rejec-
tion and 16 days (range 15-27) in patients who did not have 
it (P=O.Ol). No differences were found in the dose of CsA 
before the discontinuation among the 3 CsA patients who had 
rejection and the 4 who did not. In those patients who did 
reject, all rejection episodes were controlled with the resump-
tion of baseline immunosuppression. With a median fol· 
low-up of 942 days (range 440-2022 days), all patients who 
survived are alive, none required retransplantation. and only 
2 (11%; 1 esA and 1 FK506 patient) have signs of chronic 
rejection in their liver biopsy (5). 
The fact that most of the patients reported here had their 
immunosuppression stopped without emergence of rejection 
could be explained by more than a single mechanism. On the 
one hand,. the infection itself may produce immunosuppres-
sion, particularly viral infections (CMV or EBV), which are 
well-known immunosuppressive agents (6, 7). In addition, 
these patients were by definition iatrogenically "overimmu-
nosuppressed," as none of the 8 who came to an autopsy had 
evidence of rejection; for those who survived, a 50% reduction 
in baseline maintenance immunosuppression when this was 
resumed did not lead to rejection. 
A second explanation for the ability to stop treatment is 
that the first stage of donor recipient nonreactivity was well 
underway. This tolerance induction, which has been associ-
ated with cell migration and chimerism (8-10), allowed glo-
bal immunologic recovery without rejection of the graft. The 
variable and unpredictable completeness of this process of 
"graft acceptance" was evident even at such an early time. 
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TABLE 1. Infection, immunosuppression, and outcome in the 31 patients" 
PatIent Infection Immunosuppression Outcome 
1 CMV retinitis FK Alive 
2 CVM retinitis FK Alive 
3 CMV retinitis FK Alive 
4 CMV pneumonitis FK Died (28 days i 
5 CMV pneumonitis CSA Alive 
6 CMV + PCP pneumonitis FK Died (18 days) 
7 Disseminated CMV FK Died (27 days) 
8 Disseminated CMV FK Died (16 days) 
9 Disseminated CMV + PTLD FK Died (21 days) 
10 Disseminated TB FK Alive 
11 Dissemmated TB CSA Alive 
12 PCP pneumonia FK Alive 
13 PCP pneumonia FK Alive 
14 Aspergillosis FK Alive 
15 Aspergillosis FK Died (30 days) 
16 Aspergillosis FK Died (50 days) 
17 Cryptococcal meningitis FK Died (56 days) 
18 Cryptococcal meningitis CSA Died (21 days) 
19 Cryptococcal meningitis CSA Died (23 days) 
20 PTLD CSA Died (20 days) 
21 PTLD CSA Died (25 days) 
22 PTLD CSA Died (23 days) 
23 PTLD CSA Alive 
24 PTLD CSA Alive 
25 PTLD CSA Alive 
26 PTLD CSA Alive 
27 PTLD CSA Alive 
28 PTLD FK Alive 
29 PTLD FK Alive 
30 PTLD FK Alive 
31 PTLD FK Alive 
a PCP, Pneumocystis carinii pneumonia; PTLD, posttransplant lymphoproliferative disorder. 
Rejection emerged in 4 of the 18 survivors when reinstitution 
of treatment was withheld beyond 2 weeks, by freedom of this 
complication in the other 14. However, even in the recipients 
who developed rejection, secondary rescue therapy at a lower 
level of immunosuppression was successful in all cases. 
Reyes et al. (11) have shown that some recipients in a similar 
series of cases could be left permanently drug free, but which 
recipients cannot be predicted. 
In summary, we have shown here that in selected patients 
after liver transplantation, temporary withdrawal of immu-
nosuppression therapy may be indicated in the management 
of severe infectious complications, without the development 
of immediate rejection. Reinstitution of immunosuppression 
in reduced doses at a later time can be done on a case to case 
basis to prevent the emergence of rejection. 
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